ONS-5010 / LYTENAVA™ (bevacizumab-vikg)
Wet Age-Related Macular Degeneration (wet AMD)
Key Facts
About Outlook Therapeutics
Outlook Therapeutics is focused on developing and commercializing the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications. Its lead candidate, ONS-5010/LYTENAVA™, has achieved marketing authorization in the European Union and United Kingdom for wet AMD and is under regulatory review in the U.S. The company is strategically positioned to address a significant market need for a dedicated, approved ophthalmic anti-VEGF therapy, with commercial launch in Europe underway and preparations for a potential U.S. launch.
View full company profileAbout Outlook Therapeutics
Outlook Therapeutics is focused on developing and commercializing the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications. Its lead candidate, ONS-5010/LYTENAVA™, has achieved marketing authorization in the European Union and United Kingdom for wet AMD and is under regulatory review in the U.S. The company is strategically positioned to address a significant market need for a dedicated, approved ophthalmic anti-VEGF therapy, with commercial launch in Europe underway and preparations for a potential U.S. launch.
View full company profileAbout Outlook Therapeutics
Outlook Therapeutics is focused on developing and commercializing the first FDA-approved ophthalmic formulation of bevacizumab for retinal indications. Its lead candidate, ONS-5010/LYTENAVA™, has achieved marketing authorization in the European Union and United Kingdom for wet AMD and is under regulatory review in the U.S. The company is strategically positioned to address a significant market need for a dedicated, approved ophthalmic anti-VEGF therapy, with commercial launch in Europe underway and preparations for a potential U.S. launch.
View full company profileTherapeutic Areas
Other Wet Age-Related Macular Degeneration (wet AMD) Drugs
| Drug | Company | Phase |
|---|---|---|
| OTX-TKI (axitinib implant) | Ocular Therapeutix | Phase 3 |
| DURAVYU™ (EYP-1901) | EyePoint Pharmaceuticals | Phase 3 |
| Sozinibercept (OPT-302) | Opthea | Phase 3 |
| 4D-150 | 4D Molecular Therapeutics | Phase 3 |